Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors Zhumei ZhanWei GuoOu Bai Review Article 09 January 2023 Pages: 249 - 259
Prognostic value of multiparametric cardiac magnetic resonance in sickle cell patients Antonella MeloniLaura PistoiaFilippo Cademartiri Original Article 02 December 2022 Pages: 261 - 270
Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study Azza TantawyNayera El-SherifFatma S. E. Ebeid Original Article Open access 16 January 2023 Pages: 271 - 281
Comparative efficacy and safety of restrictive versus liberal transfusion thresholds in anemic preterm infants: a meta-analysis of 12 randomized controlled trials Xiaoling FuXingdan ZhaoQian Zhang Original Article Open access 21 December 2022 Pages: 283 - 297
Long noncoding RNA FAM157C contributes to clonal proliferation in paroxysmal nocturnal hemoglobinuria Honglei WangHui LiuRong Fu Original Article Open access 06 January 2023 Pages: 299 - 309
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study Ulrich GermingPierre FenauxGuillermo Garcia-Manero Original Article Open access 13 January 2023 Pages: 311 - 321
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy Piroska KlementWalter FiedlerMichael Heuser Original Article Open access 28 December 2022 Pages: 323 - 328
Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment Weijia FuYue HuJianmin Yang Original Article 12 January 2023 Pages: 329 - 335
Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia Yun-wei ZhangLong SuSu-jun Gao Original Article 15 November 2022 Pages: 337 - 347
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group Steffen KoschmiederSusanne Isfortfor the German Study Group for Myeloproliferative Neoplasms (GSG-MPN) Original Article Open access 23 December 2022 Pages: 349 - 358
Prognostic significance of absolute monocyte count and lymphocyte to monocyte ratio in mucosa-associated lymphoid tissue (MALT) lymphoma Chun-Yu ShangJia-Zhu WuWei Xu Original Article 10 January 2023 Pages: 359 - 367
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma Yubin KangPasupathi SundaramoorthyTerry Plasse Original Article 03 December 2022 Pages: 369 - 383
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma Francesco GaudioGiacomo LosetoPellegrino Musto Original Article 16 January 2023 Pages: 385 - 392
Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab Fei WangLuo LuWeiying Gu Original Article 21 January 2023 Pages: 393 - 402
BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2 Judith KonratWiebke RöslerThorsten Zenz Original Article Open access 10 December 2022 Pages: 403 - 406
Allogeneic stem cell transplantation in patients with a prior history of prostate cancer Raffaele PalmieriRobert B. MontgomeryKristine Doney Original Article 17 November 2022 Pages: 407 - 412
Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation K. EngerX. TonnarH. Bertz Original Article Open access 03 December 2022 Pages: 413 - 420
Exposure of anti-infective drugs and the dynamic changes of the gut microbiota during gastrointestinal mucositis in autologous stem cell transplant patients: a pilot study Anne-Grete MärtsonAna Rita da Silva FerreiraJan-Willem C. Alffenaar Original Article Open access 17 January 2023 Pages: 421 - 427
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma Carmen MartínezManuel Espeso de Haroon behalf of Grupo Español de Linfoma y Trasplante de Médula Ósea (GELTAMO) y Grupo Español de Trasplante (GETH) Original Article 12 November 2022 Pages: 429 - 437
The association between nutritional risk index and ICU outcomes across hematologic malignancy patients with acute respiratory failure Riddhi KunduRena SeegerLaveena Munshi Original Article 21 December 2022 Pages: 439 - 445
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain Ariana OrtuzarMaría Laura FoxSantiago Osorio Original Article 23 November 2022 Pages: 447 - 456
Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura Benson MeekNuti DesaiJustin Arnall Letter to the Editor 28 November 2022 Pages: 457 - 459
Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy James A. DavisJagoda MisniakiewiczBrian T. Hess Letter to the Editor 16 November 2022 Pages: 461 - 462
Impact of antithymocyte globulin on blood cyclosporin A levels in aplastic anemia patients Yuya FutagiYukio SugaYoshimichi Sai Letter to the Editor 26 November 2022 Pages: 463 - 465
Magnitude of cumulative iron overload correlates with the severity of anemia in untreated non-transfusion-dependent β-thalassemia Khaled M. MusallamMaria Domenica CappelliniAli T. Taher Letter to the Editor 14 November 2022 Pages: 467 - 469
EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia Adam SulemanHubert TsuiLee Mozessohn Letter to the Editor 28 November 2022 Pages: 471 - 472
Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT Haimin SunHan YanSujiang Zhang Letter to the Editor 24 November 2022 Pages: 473 - 475
Inherited transmission of the CSF3R T618I mutation: a familial report Istemi SerinTahir Alper CinliOsman Yokus Letter to the Editor 15 November 2022 Pages: 477 - 479
Neurolymphomatosis of cranial nerves as the responsible lesions for the vocal cord paralysis and facial nerve palsy in a patient with diffuse large B-cell lymphoma Yu InoueKoichi HirakawaJunya Kuroda Letter to the Editor 14 November 2022 Pages: 481 - 482
Disseminated Mycobacterium haemophilum infection during alemtuzumab treatment of T-cell prolymphocytic leukemia Carol Y. M. CheungRock Y. Y. LeungYok-lam Kwong Letter to the Editor 13 January 2023 Pages: 483 - 485
Vinblastine as a bridge to 7 + 3 in acute myeloid leukaemia Fernando De la Garza-SalazarAndrés Gómez-De LeónPerla R. Colunga-Pedraza Letter to the Editor 18 January 2023 Pages: 487 - 489
Early cerebrospinal fluid infiltration in TP53-mutated blastic plasmacytoid dendritic cell neoplasm Simon MichaelisAngelika PichlerDietmar Enko Letter to the Editor 16 December 2022 Pages: 491 - 493
The KMT2A rearrangement is an early event prior to KMT2A-PTD in AML patients with both molecular aberrations Jiayu HuangYongmei ZhuSujiang Zhang Letter to the Editor 16 December 2022 Pages: 495 - 497
Therapy-related myelodysplastic syndrome with monosomy 7 and metastatic renal cell carcinoma successfully treated with nivolumab: two birds with one stone Lana Jajac BručićIvan Krečak Letter to the Editor 20 December 2022 Pages: 499 - 500
Correction to: A real‑world experience of eltrombopag plus rabbit antithymocyte immunoglobulin–based IST in Chinese patients with severe aplastic anemia Yuanyuan JinRuixin LiJiangyong Li Correction 26 January 2023 Pages: 501 - 501